FOLH1 and xerostomia: Xerostomia emerges as the most frequently reported adverse effect of [225Ac]Ac-PSMA RLT, attributable to the physiological expression of PSMA in salivary glands and the high energy deposition of alpha particles in small glandular tissue volumes (Table 2).